2020-12-16 09:41:25

HO WAH GENTING BERHAD OFFERS RELIABLE AND ACCURATE POST COVID-19 VACCINE ANTIBODY DETECTION KITS

- NAbs detection kits can confirm and monitor vaccine effectiveness

KUALA LUMPUR, 16 DECEMBER 2020 – Ho Wah Genting Berhad (“HWGB” or the “Company”) (Bursa Stock Code: 9601) wholly-owned subsidiary, HWGB Medical Devices & Supplies Sdn Bhd (“HWGB Medical Devices”), is rolling out a post COVID-19 vaccine antibody detection kit that is the SARS-CoV-2 Neutralizing Antibody (NAbs) Detection Kit as an accurate and reliable way to detect the effectiveness of the COVID-19 vaccines that will be administered soon to frontliners and the vulnerable groups.
 
The NAbs detection kits play a crucial role in confirming the production of antibodies following the administering of COVID-19 vaccines and monitor the effectiveness of the vaccine in combatting the virus and detect its eradication. The kits are also accurate, fast and accessible, which is important given the need for speed and accuracy in confirming vaccine effectiveness and success rates.
 
Chief Medical Consultant of HWGB Biotech Sdn Bhd, Dato' Dr Lai Kwong Choy said: “We need detection kits that are accurate to understand more on the effectiveness of the COVID-19 vaccines. This will provide us insight on how to fight COVID-19 in a more efficient way”.
 
"The speed and accessibility are also important because the number of infected people in our country is rising, the public will feel safer with our detection kit as this will give them reassurance on the effectiveness of the COVID-19 vaccines”.
 
HWGB Medical Devices was authorised by Wenzhou OJA Biotechnology Co. Ltd (“WOJA”) to be the exclusive distributor of the NAbs detections kits in Malaysia and Indonesia in a letter of authorization dated 10 December 2020.
 
WOJA was founded to focus on the development of testing solutions for COVID-19 and prior to the pandemic's outbreak, the founders of WOJA and its panel of medical experts was working on perfecting the methods to accurately and efficiently diagnose various diseases and viruses. WOJA is also an extension of BIOSIC, a company specialising in early cancer detection and disease diagnosis.



Ho Wah Genting Berhad (“HWGB” or the “Company”) is principally engaged in investment holdings and the provision of management services to its subsidiaries. The Company had on 30 June 2020 diversified its existing businesses to include healthcare related industry which mainly involved in health supplement, biotechnology and health technology. In addition, the Company and its subsidiaries (“HWGB Group” or the “Group”) are also engaging in the businesses of investment holdings; manufacturing of wires and cables and moulded power supply cord sets and cable assemblies for electrical and electronic devices and equipment; trading of wires and cables; and travel agent and tour related services.

Please refer to the US Food and Drug Administration website for more information on EBI’s Phase IV clinical study: https://www.clinicaltrials.gov/ct2/show/NCT04639375

Dato’ Dr.Lai Kwong Choy, Chief Medical Consultant of HWGB Biotech
A medical doctor with practices at various clinics with over 30 year of relevant experience in the medical field. He is also the former board member of Malaysia Health Promotion Board under the MOH and has served as a local counsellor at the Kajang Municipal Council.
 


Wenzhou OJA Biotechnology Co. Ltd (“WOJA”)  was founded in April 2020 by Dr. Wang Jin Gu, who has more than 10 years of experience in in-vitro diagnostics field, as an extension of BIOSIC; a company that specializes in early cancer detection and disease diagnostic.  WOJA was formed to focus on the development of testing solutions for the SARS-CoV-2. Prior to the outbreak of the COVID-19 epidemic, the founders and the panel of medical experts had been working on perfecting methods to accurately and efficiently diagnose various diseases and viruses.

 

Back